Researchers have revealed new details about the CRISPR-Cas5-HNH/Cascade complex, a variant of the type I-E CRISPR-Cas system, ...

The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...

According to the experts, humans will look a lot more uniform in the future. They predict the average person will have darker ...

Deregulating New Zealand's gene tech space has been long-desired, but critics say the Government's growth-focused approach ...

The innovation, he says, could transform the way scientists measure and address genomic breaks in gene-editing systems.

Casgevy is a one-time therapy that uses CRISPR/Cas9 gene-editing technology to modify a patient ... now allows Casgevy to be made available under a managed-access scheme, meaning further data will be ...